摘要
目的评价恩替卡韦抗病毒治疗慢性乙型肝炎(CHB)48周的疗效和安全性。方法187例CHB患者随机分为治疗组和对照组,治疗组(118例)予恩替卡韦0.5 mg,1次/d,口服,对照组(69例)予以拉米夫定100mg,1次/d,口服。结果治疗组治疗4周和8周时HBV DNA水平较治疗前显著下降,治疗12周,HBV DNA下降至检测水平以下(<1×103拷贝/ml)比例为57.6%,显著优于对照组,表现出较高的抗病毒早期应答率;治疗24周和48周时,HBV DNA下降至检测水平以下(<103拷贝/ml)比例为81.3%和92.3%,与对照组比较差异显著;48周时HBeAg阴转率为23.7%,肝功能复常率为98.3%,且无耐药患者出现。治疗过程中未发生与观察药物相关的严重不良反应。结论恩替卡韦能快速、强效地抑制乙肝病毒复制,安全性和耐受性良好。
Objective To evaluate the 48 weeks therapeutic effects and safety of anti-virus therapy of entecavir in patients with chronic hepatitis B （CHB）. Methods 187 CHB eases were divided into the treated group （ 118 ） and the control group （69） randomly. Patients were given entecarvir （0. 5mg po qd ）in the treated group, while the others were given lamivudine （ 100mg po qd） in the control group. Results In the treated group,the levels of serum HBV DNA was obviously decreased than that before treatment at the 4^th and 8^th week; at the 12^th week, the ratio of negative transformation of HBV DNA was 57.6%, which was superior to the control group,there was higher ratio of early reponse of anti-virus therapy; at the 24^th and 48^th week, the ratios of negative transformation of HBV DNA were 81.3% and 92.3%, there were significent difference between these two groups; at the 48^th week the ratio of negative transformation of HBeAg was separately 28. 8% and the ratio of recovery of liver function was 98.3% ,and there was no drug-resistant case ,it demonstrated favourable reaction of sustained response. There was no serious adverse event related with entecavir. Conclusion Entecavir can inhibit the replication of hepatitis B virus and have good safety and tolerance.
出处
《四川医学》
CAS
2009年第12期1894-1896,共3页
Sichuan Medical Journal
